Randomized, open-label study of bintrafusp alfa vs. pembrolizumab as first-line (1L) treatment in patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC)

by on 8 de març de 2021 with No hi ha comentaris
  • Ahn, M. -., Barlesi, F., Felip, E., Garon, E., Martin, C. M., Vokes, E., et al. (2021). Randomized, open-label study of bintrafusp alfa vs. pembrolizumab as first-line (1L) treatment in patients with PD-L1-expressing advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 16(1), S27-S28. https://doi.org/10.1016/j.jtho.2020.10.134

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *